Action Ocugen - OCGN

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

0,6051

Prix Achat

0,55

Prix Vente

3,00

Volume échangé

2 970 916

0,603 Fourchette du Jour 0,639999

0,552 Plage de 52 semaines 2,105

Cap du marché

176,278M

Clôture Veille

0,6306

Ouverture

0,6297

Dernière Transaction

1500

0.6051

(formt)

Dernière heure de transaction

Volume financier

US$ 1 838 434

VWAP

0,618811

Volume moyen (3 m)

4 706 458

Actions en circulation

291 320 280

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,82

Bénéfice par action (BPA)

-0,22

Chiffre d'affairess

6,04M

Bénéfice net

-63,08M

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Ortho,prosth,surg Appl,suply

Site Web

ocugen.com

Siège social

Wilmington, Delaware, USA

Fondé

2020

Ocugen Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker OCGN. Le dernier cours de clôture d'Ocugen était de US$0,63. Au cours de la dernière année, les actions de Ocugen ont été négociées dans une fourchette de prix de US$ 0,552 à US$ 2,105.

Ocugen compte actuellement 291 320 280 actions en circulation. La capitalisation boursière d'Ocugen est de US$183,71 million. Ocugen a un ratio cours/bénéfice (ratio PE) de -2.82.

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt...

Form 8-K - Current report

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...

Form 8-K - Current report

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.015	-2.41896468312	0.6201	0.6876	0.552	4917085	0.61057262	CS
4	-0.12315	-16.9104016478	0.72825	0.7545	0.552	3984612	0.652328	CS
12	-0.2414	-28.5174246899	0.8465	0.99	0.552	4706458	0.74577056	CS
26	-0.5449	-47.3826086957	1.15	1.2675	0.552	4081792	0.86241558	CS
52	-0.2849	-32.0112359551	0.89	2.105	0.552	5610522	1.29245408	CS
156	-1.7449	-74.2510638298	2.35	4.03	0.345	5587285	1.43400129	CS
260	0.1711	39.4239631336	0.434	18.77	0.17	16754119	5.41940838	CS

OCGN - Frequently Asked Questions (FAQ)

What is the current Ocugen share price?

The current share price of Ocugen is US$ 0,6051

How many Ocugen shares are in issue?

Ocugen has 291 320 280 shares in issue

What is the market cap of Ocugen?

The market capitalisation of Ocugen is USD 183,71M

What is the 1 year trading range for Ocugen share price?

Ocugen has traded in the range of US$ 0,552 to US$ 2,105 during the past year

What is the PE ratio of Ocugen?

The price to earnings ratio of Ocugen is -2,82

What is the cash to sales ratio of Ocugen?

The cash to sales ratio of Ocugen is 29,47

What is the reporting currency for Ocugen?

Ocugen reports financial results in USD

What is the latest annual turnover for Ocugen?

The latest annual turnover of Ocugen is USD 6,04M

What is the latest annual profit for Ocugen?

The latest annual profit of Ocugen is USD -63,08M

What is the registered address of Ocugen?

The registered address for Ocugen is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Ocugen website address?

The website address for Ocugen is ocugen.com

Which industry sector does Ocugen operate in?

Ocugen operates in the ORTHO,PROSTH,SURG APPL,SUPLY sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	577,55k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,59M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,18M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108,27k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	336,99k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	341,94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	143,04M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	142,23M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ocugen Inc (OCGN) Cours

Ocugen Inc (OCGN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Ocugen Inc

OCGN Dernières nouvelles

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Form 8-K - Current report

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Form 8-K - Current report

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Form 8-K - Current report

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Form 8-K - Current report

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Form 8-K/A - Current report: [Amend]

OCGN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités